LSE - Delayed Quote GBp

GSK plc (GSK.L)

1,640.50

+4.50

(+0.28%)

At close: 4:29 PM GMT+1

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

Business Wire last month
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise

Business Wire last month
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD. AL101 is an investigational human

GlobeNewswire 2 months ago
23andMe Reports Third Quarter Fiscal 2024 Financial Results

Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the

GlobeNewswire 2 months ago
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of FTD-GRN- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monocl

GlobeNewswire 2 months ago
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

PHILADELPHIA, February 06, 2024--GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

Business Wire 2 months ago
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

SAN CARLOS, Calif., January 24, 2024--GSK has signed a collaboration & licensing agreement to leverage Elegen's cell-free DNA manufacturing tech in the dev of GSK’s vaccines & medicines.

Business Wire 2 months ago
GSK Enters Agreement to Acquire Aiolos Bio

SAN FRANCISCO & LONDON, January 09, 2024--GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.

Business Wire 3 months ago
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

PHILADELPHIA, December 12, 2023--GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

Business Wire 4 months ago
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

PHILADELPHIA, November 13, 2023--GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

Business Wire 5 months ago
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe database for novel drug target discovery and other researchSOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which extends their collaboration and enables GSK to c

GlobeNewswire 5 months ago
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a

GlobeNewswire 5 months ago
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

PHILADELPHIA, October 25, 2023--New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease

Business Wire 5 months ago
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

GlobeNewswire 6 months ago
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

LONDON, September 15, 2023--Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

Business Wire 7 months ago
GSK and Earvin "Magic" Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

PHILADELPHIA, September 05, 2023--GSK and Earvin "Magic" Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

Business Wire 7 months ago
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies

PHILADELPHIA, August 17, 2023--GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine, is now available at all major US retail pharmacies

Business Wire 8 months ago
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

LONDON, July 31, 2023--Jemperli (dostarlimab-gxly) plus chemo approved in US as new frontline treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Business Wire 8 months ago
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

PHILADELPHIA, July 13, 2023--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).

Business Wire 9 months ago
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023.

CNW Group 9 months ago

Performance Overview

Return	GSK.L	FTSE 100
YTD	+14.22%	+4.43%
1-Year	0.00%	+2.07%
3-Year	+40.52%	+16.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GSK plc (GSK.L)

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

23andMe Reports Third Quarter Fiscal 2024 Financial Results

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

GSK Enters Agreement to Acquire Aiolos Bio

GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

GSK and Earvin "Magic" Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

Performance Overview